M
Martin E. Goldman
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 107
Citations - 6788
Martin E. Goldman is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Mitral valve & Atrial fibrillation. The author has an hindex of 33, co-authored 106 publications receiving 6223 citations. Previous affiliations of Martin E. Goldman include City University of New York & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in Atrial Fibrillation III Randomised Clinical Trial
Joseph L. Blackshear,Vickie S. Baker,F. Rubino,Robert E. Safford,Gary E. Lane,T. Flipse,J. Malouf,Randall C. Thompson,Richard Webel,Greg C. Flaker,L. Young,David C Hess,G. Friedman,R. Burger,John H. McAnulty,Bruce M. Coull,Christy Marchant,J. Timberg,C. Janzik,G. Giraud,B. Halperin,J. Kron,M. Wynn,M. Raitt,David C. Anderson,Richard W. Asinger,S. M. Newburg,J. Fifield,S. R. Bundlie,Richard L. Koller,R. D. Tarrel,C. Dick,J. M. Haugland,C. R. Jorgensen,Anne D. Leonard,Merrill C. Kanter,Diane H. Solomon,Miguel Zabalgoitia,D. Mego,John E. Carter,S. Y. Boyd,Bradley S. Boop,D. LaLonde,R. Modlin,William R. Logan,B. J. Green,William P. Hamilton,L. Mezei,S. Riggio,George Feldman,Arthur D. Hayward,R. Strauss,W. Anderson,J. Grover,M. McKenzie,P. Hart-McArthur,M. Gramberg,H. Houston,Jonathan L. Halperin,E. B. Rothauf,Jesse Weinberger,Martin E. Goldman,Andreas Laupacis,K. L. Chan,P. Bourque,J. Biggs,A. Ives,William M. Feinberg,Karl B. Kern,Gregory D. Pennock,Paul E. Fenster,B. J. Huerta,J. Ohm,Howard C. Dittrich,C. Kerridge,W. Keen,M. Swenson,Stephen L. Kopecky,Scott C. Litin,David O. Wiebers,Anne E. Holland,Ronald D. Brown,B. K. Khandheria,I. Meissner,K. R. Tucker,Robert M. Rothbart,J. Torelli,J. Schmidt,D. Murray,R. S. Ruzich,H. Loutfi,Christopher P. Appleton,T. Ingall,L. Carlson,D. Wilson,M. Dunn,B. Nolte,C. Edwards,A. Dick,L. A. Price,Denise L. Janosik,P. Bjerregaard,A. Quattromani,L. Schiller,Arthur J. Labovitz,C. Burch,B. J. Parks,D. Thompson,L. Berarducci,S. Carey,A. Vigil,Rodney H. Falk,N. Battinelli,M. McNeil,R. Davidoff,Sheilah Bernard,P. Bergethon,L. Fiori,Gregory W. Albers,E. Atwood,J. Clark,D. Tong,Midori A. Yenari,V. Froelicker,H. Lutsep,N. H. Hock,S. Quaglietti,S. Kemp,M. A. Alpert,J. F. Rothrock,C. H. Hupp,C. V. Massey,W. J. Hamilton,V. T. Miller,J. Fox,RichardA. Kronmal,Ruth McBride,E. Nasco,Lesly A. Pearce,K. Fletcher,Jodi Koehler,Robert G. Hart,David G. Sherman,R. L. Talbert,P. A. Heberling,C. Kajzer,EG Bovill,D. Geffken,E. Cornell,S. Nightingale,S. P. Kelsy,David E. Levy,J. D. Marsh,K. M.A. Welch,John R. Marler,M. D. Walker +155 more
TL;DR: Low-intensity, fixed-dose warfarin plus aspirin in this regimen is insufficient for stroke prevention in patients with non-valvular AF at high-risk for thromboembolism; adjusted-doseWarfarin (target INR 2.0-3.0) importantly reduces stroke for high- risk patients.
Journal ArticleDOI
Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.
Robert J. Desnick,Roscoe O. Brady,John A. Barranger,Allan J. Collins,Dominique P. Germain,Martin E. Goldman,Gregory A. Grabowski,Seymour Packman,William R. Wilcox +8 more
TL;DR: Recently, enzyme replacement with human -Gal A has been shown to safely reverse the pathogenesis of the major clinical manifestations, to decrease pain, and to stabilize renal function in patients with Fabry disease, and the European Agency for the Evaluation of Medicinal Products has approved the treatment and the U.S. Food and Drug Administration is currently reviewing it.
Journal ArticleDOI
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.
Christine M. Eng,Maryam Banikazemi,Ronald E. Gordon,Martin E. Goldman,Robert G. Phelps,Leona Kim,Alan Gass,Jonathan A. Winston,Steven Dikman,John T. Fallon,Scott E. Brodie,Charles B. Stacy,Davendra Mehta,Rosaleen Parsons,Karen I. Norton,Michael O'Callaghan,Robert J. Desnick +16 more
TL;DR: A single-center, open-label, dose-ranging study of r-halphaGalA treatment in 15 patients, each of whom received five infusions at one of five dose regimens provides the basis for a phase 3 trial of enzyme-replacement therapy for Fabry disease.
Journal ArticleDOI
Cardiac Involvement in Patients with Sarcoidosis: Diagnostic and Prognostic Value of Outpatient Testing
Davendra Mehta,Steven A. Lubitz,Zev Frankel,Juan P. Wisnivesky,Andrew J. Einstein,Martin E. Goldman,Josef Machac,Alvin S. Teirstein +7 more
TL;DR: A structured clinical assessment incorporating advanced cardiac imaging with PET scanning or CMRI is more sensitive than the established criteria for the identification of CS in ambulatory patients with preserved cardiac function, who appear to be at low risk for short-term mortality.
Journal ArticleDOI
In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography.
Zahi A. Fayad,Tamana Nahar,John T. Fallon,Martin E. Goldman,J. Gilberto Aguinaldo,Juan J. Badimon,Meir Shinnar,James H. Chesebro,Valentin Fuster +8 more
TL;DR: This study demonstrates that noninvasive MR evaluation of the aorta compares well with TEE imaging for the assessment of atherosclerotic plaque thickness, extent, and composition.